Jean-Francois Leprince
Chief Executive Officer at GLyPharma Therapeutic, Inc.
Profile
Jean-Francois Leprince is currently the Chief Executive Officer & Director at GLyPharma Therapeutic, Inc., a Director at ILKOS THERAPEUTICS, Inc., and a Managing Partner Funds I & II at CTI Capital, Inc. Previously, he held positions as a Director at Montréal International, Somnus Therapeutics, Inc., and Chlorion Pharma, Inc. He also served as the Principal at The Dow Chemical Co. and Benelux Real Estate AG from 1979 to 2004.
Additionally, he was the President of Aventis Pharmaceuticals, Inc. from 1998 to 2004 and the President-Health Management Research at the University of Montréal.
Furthermore, he held the position of President at Hoechst Marion Roussel, Inc. from 1998 to 2004.
Jean-Francois Leprince active positions
| Companies | Position | Start |
|---|---|---|
GLyPharma Therapeutic, Inc.
 GLyPharma Therapeutic, Inc. BiotechnologyHealth Technology GLyPharma Therapeutic, Inc. develops oncology therapeutic treatment. It engages in the development of the clinical efficacy of FE 203799, a novel proprietary Glucagon-Like Peptide-2(GLP-2) analogue exerting unique pharmacological effects in a first-in-class, meaningful indication for patients with hematological malignancies receiving myelotoxic therapies. The company was founded in August 2012 and is headquartered in Montreal, Canada. | Chief Executive Officer | - |
ILKOS THERAPEUTICS, Inc.
 ILKOS THERAPEUTICS, Inc. BiotechnologyHealth Technology ILKOS THERAPEUTICS, Inc. operates as biotechnology firm. It develops drug and clinical solutions for the treatment of venous lower limb ulcers. The company is headquartered in Laval, Canada. | Director/Board Member | - |
CTI Capital, Inc.
 CTI Capital, Inc. Investment ManagersFinance CTI Capital, Inc. is a Venture Capital firm, a subsidiary of CTI Capital Groupe, Inc. founded in 1987. CTI Capital, Inc. is headquartered in Montréal. | Private Equity Investor | - |
Former positions of Jean-Francois Leprince
| Companies | Position | End |
|---|---|---|
| Hoechst Marion Roussel, Inc. | President | 2003-12-31 |
Aventis Pharmaceuticals, Inc.
 Aventis Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Aventis Pharmaceuticals, Inc. develops, manufactures and markets pharmaceutical products. The company was founded in 1950 and is headquartered in Bridgewater, NJ. | President | 2003-12-31 |
Benelux Real Estate AG
 Benelux Real Estate AG Real Estate DevelopmentFinance Part of AGIV Real Estate AG, Benelux Real Estate AG engages in real estate development. | Corporate Officer/Principal | 2003-12-31 |
Somnus Therapeutics, Inc.
 Somnus Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Somnus Therapeutics, Inc. operates as a pharmaceutical company. It develops therapeutics to address the need of insomnia patients. The company was founded by Gary C. Cupit in June 2007 is headquartered in Branchburg, NJ. | Director/Board Member | - |
| University of Montréal | Corporate Officer/Principal | - |
Experiences
Positions held
Active
Inactive
Listed companies
Private companies
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Private companies | 10 |
|---|---|
The Dow Chemical Co.
 The Dow Chemical Co. Chemicals: SpecialtyProcess Industries The Dow Chemical Co. engages in the manufacture and distribution of chemicals, plastics, industrial and agricultural products. It serves agriculture, automotive, building and construction, consumer, electronic materials, infrastructure, packaging, product finder and product safety industries. The company was founded by Herbert Henry Dow in 1897 and is headquartered in Midland, MI. | Process Industries |
Aventis Pharmaceuticals, Inc.
Aventis Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Aventis Pharmaceuticals, Inc. develops, manufactures and markets pharmaceutical products. The company was founded in 1950 and is headquartered in Bridgewater, NJ. | Health Technology |
CTI Capital, Inc.
CTI Capital, Inc. Investment ManagersFinance CTI Capital, Inc. is a Venture Capital firm, a subsidiary of CTI Capital Groupe, Inc. founded in 1987. CTI Capital, Inc. is headquartered in Montréal. | Finance |
Benelux Real Estate AG
Benelux Real Estate AG Real Estate DevelopmentFinance Part of AGIV Real Estate AG, Benelux Real Estate AG engages in real estate development. | Finance |
Montréal International
 Montréal International Miscellaneous Commercial ServicesCommercial Services Montréal International attracts and promotes economic development of Greater Montreal. The company was founded in 1996 and is headquartered in Montréal, Canada. | Commercial Services |
| Hoechst Marion Roussel, Inc. | |
GLyPharma Therapeutic, Inc.
GLyPharma Therapeutic, Inc. BiotechnologyHealth Technology GLyPharma Therapeutic, Inc. develops oncology therapeutic treatment. It engages in the development of the clinical efficacy of FE 203799, a novel proprietary Glucagon-Like Peptide-2(GLP-2) analogue exerting unique pharmacological effects in a first-in-class, meaningful indication for patients with hematological malignancies receiving myelotoxic therapies. The company was founded in August 2012 and is headquartered in Montreal, Canada. | Health Technology |
ILKOS THERAPEUTICS, Inc.
ILKOS THERAPEUTICS, Inc. BiotechnologyHealth Technology ILKOS THERAPEUTICS, Inc. operates as biotechnology firm. It develops drug and clinical solutions for the treatment of venous lower limb ulcers. The company is headquartered in Laval, Canada. | Health Technology |
Somnus Therapeutics, Inc.
Somnus Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Somnus Therapeutics, Inc. operates as a pharmaceutical company. It develops therapeutics to address the need of insomnia patients. The company was founded by Gary C. Cupit in June 2007 is headquartered in Branchburg, NJ. | Health Technology |
Chlorion Pharma, Inc.
 Chlorion Pharma, Inc. Miscellaneous Commercial ServicesCommercial Services Chlorion Pharma, Inc. Develops small molecule leads for the treatment of naturopathic pain and epilepsy. It develops therapeutics for the treatment of neuropathic pain and epilepsy. The company was founded by Jeffrey A. M. Coull, Yves De Koninck and Martin Gagnon in 2004 and is headquartered in Laval, Canada. | Commercial Services |
- Stock Market
- Insiders
- Jean-Francois Leprince
